SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amc - Quaterly Results

14 Feb 2024 Evaluate
The company witnessed a 10.74% growth in the revenue at Rs. 868.20 millions for the quarter ended December 2023 as compared to Rs. 784.00 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -181.80 millions as compared to Net Loss of Rs. -65.40 millions of corresponding quarter ended December 2022The company reported a good operating profit of 162.80 millions compared to 91.60 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 868.20 784.00 10.74 2160.90 2894.20 -25.34 4025.50 3066.10 31.29
Other Income 131.10 123.60 6.07 662.60 373.70 77.31 521.60 603.90 -13.63
PBIDT 162.80 91.60 77.73 614.90 387.50 58.68 599.20 999.00 -40.02
Interest 171.40 146.60 16.92 523.20 408.80 27.98 579.20 372.30 55.57
PBDT -8.60 -75.00 -88.53 61.20 -41.30 -248.18 0.00 567.60 -100.00
Depreciation 262.20 28.90 807.27 754.90 727.40 3.78 962.00 1400.70 -31.32
PBT -270.80 -103.90 160.64 -693.70 -768.70 -9.76 -962.00 -833.10 15.47
TAX -89.00 -38.50 131.17 -240.80 -282.20 -14.67 -373.30 -528.40 -29.35
Deferred Tax -89.00 -38.50 131.17 -240.80 -282.20 -14.67 -373.30 -221.60 68.46
PAT -181.80 -65.40 177.98 -452.90 -486.50 -6.91 -588.70 -304.70 93.21
Equity 313.60 313.60 0.00 313.60 313.60 0.00 313.60 313.60 0.00
PBIDTM(%) 18.75 11.68 60.49 28.46 13.39 112.53 14.89 32.58 -54.32

Dishman Carbogen Amc Share Price

167.60 -1.00 (-0.59%)
20-Apr-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 935.00
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×